Marsh & McLennan Companies, Inc.
176.84USD
-3.6800 (-2.04%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.97▼ | $1.98 | 2 | 3 |
| Next quarter | $2.23▲ | $2.22 | 2 | 3 |
| Current year | $10.45▲ | $10.4 | 4 | 2 |
| Next year | $11.41▲ | $11.32 | 4 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.89 | $2.96 | +0.07 (+2.3%) |
| 2026-03-31 | $3.22 | $3.29 | +0.07 (+2.1%) |
| 2025-12-31 | $1.97 | $2.12 | +0.15 (+7.5%) |
| 2025-09-30 | $1.78 | $1.85 | +0.07 (+4.1%) |
56 ratings from 17 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Equal-Weight | $180 $200 | Aug 19, 2026 |
| UBS | Maintained | Buy | $212 $216 | Jul 27, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $186 $188 | Jul 22, 2026 |
| Mizuho | Maintained | Neutral | $197 $201 | Jul 22, 2026 |
| Citigroup | Downgraded from Buy | Neutral | $200 | Jul 22, 2026 |
| JP Morgan | Maintained | Overweight | $206 $212 | Jul 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $236 $234 | Jul 10, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $210 $218 | Jul 9, 2026 |
| Mizuho | Maintained | Neutral | $194 $197 | Jul 9, 2026 |
| UBS | Maintained | Buy | $203 $212 | Jul 8, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $180 $175 | Jul 6, 2026 |
| UBS | Maintained | Buy | $230 $203 | Jun 9, 2026 |
| Piper Sandler | Maintained | Neutral | $190 $182 | May 26, 2026 |
| Citigroup | Upgraded from Neutral | Buy | $200 | May 6, 2026 |
| Keefe, Bruyette & Woods | Maintained | Market Perform | $200 $203 | Apr 17, 2026 |
| B of A Securities | Maintained | Underperform | $181 $174 | Apr 14, 2026 |
| Mizuho | Maintained | Neutral | $199 $193 | Apr 13, 2026 |
| JP Morgan | Maintained | Overweight | $226 $206 | Apr 9, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $203 $178 | Apr 9, 2026 |
| Barclays | Maintained | Overweight | $209 $206 | Apr 8, 2026 |
| Keefe, Bruyette & Woods | Maintained | Market Perform | $206 $200 | Apr 7, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $195 $190 | Apr 6, 2026 |
| Barclays | Maintained | Overweight | $210 $209 | Mar 11, 2026 |
| Mizuho | Downgraded from Outperform | Neutral | $213 $199 | Feb 27, 2026 |
| Raymond James | Upgraded from Outperform | Strong Buy | $240 $225 | Feb 17, 2026 |
89 filings from 21 insiders · 12 buy / 8 sell over 6m
Officers and directors of MRSH, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brennan KatherineOfficer, SVP and General Counsel | ExerciseStock Options (Right to Buy) | 1.2k | — | — | Sep 2, 2026 |
| Brennan KatherineOfficer, SVP and General Counsel | Sell | 1.2k | $187.90 | $225k | Sep 2, 2026 |
| Brennan KatherineOfficer, SVP and General Counsel | Exercise | 1.2k | $83.05 | $99k | Sep 2, 2026 |
| Doyle John QOfficer, President and CEO | ExerciseStock Options (Right to Buy) | 16.7k | — | — | Sep 2, 2026 |
| Doyle John QOfficer, President and CEO | Sell | 16.7k | $188.51 | $3.14M | Sep 2, 2026 |
| Doyle John QOfficer, President and CEO | Exercise | 16.7k | $73.19 | $1.22M | Sep 2, 2026 |
| BROUSSARD BRUCE D.Director | Grant | 192 | $188.44 | $36k | Aug 14, 2026 |
| MILLS STEVEN ADirector | Grant | 194 | $188.44 | $37k | Aug 14, 2026 |
| JONES JOHN JUDEOfficer | Sell | 6.5k | $191.96 | $1.25M | Aug 6, 2026 |
| BESWICK PAULChief Technology Officer | Sell | 713 | $198.00 | $141k | Jul 29, 2026 |
| SOUTH MARTINOfficer | Sell | 7.1k | $189.99 | $1.35M | Jul 28, 2026 |
| YATES LLOYD MDirector | Sell | 12.0k | $175.65 | $2.11M | Jul 23, 2026 |
| DOYLE JOHN QChief Executive Officer | Sell | 16.7k | $161.71 | $2.69M | Jun 2, 2026 |
| DOYLE JOHN QChief Executive Officer | Exercise | 16.7k | $73.20 | $1.22M | Jun 2, 2026 |
| HANWAY H EDWARDDirector | Grant | 1.3k | $159.28 | $215k | Jun 1, 2026 |
| BROUSSARD BRUCE D.Director | Grant | 1.3k | $159.28 | $215k | Jun 1, 2026 |
| MILLS STEVEN ADirector | Grant | 1.3k | $159.28 | $215k | Jun 1, 2026 |
| HARTMANN JUDITHDirector | Grant | 1.3k | $159.28 | $215k | Jun 1, 2026 |
| HARRISON PETERDirector | Grant | 1.3k | $159.28 | $215k | Jun 1, 2026 |
| MILLS STEVEN ADirector | Grant | 264 | $160.60 | $42k | May 15, 2026 |
No analyst notes on MRSH yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 15 | 0 | 1 | Hold2.70 |
| 1 mo ago | 2 | 5 | 15 | 0 | 1 | Hold2.70 |
| 2 mo ago | 3 | 6 | 13 | 0 | 1 | Hold2.57 |